Logo image of GLUE

MONTE ROSA THERAPEUTICS INC (GLUE) Stock Fundamental Analysis

NASDAQ:GLUE - Nasdaq - US61225M1027 - Common Stock - Currency: USD

5.23  -0.03 (-0.57%)

After market: 5.23 0 (0%)

Fundamental Rating

4

Taking everything into account, GLUE scores 4 out of 10 in our fundamental rating. GLUE was compared to 558 industry peers in the Biotechnology industry. While GLUE seems to be doing ok healthwise, there are quite some concerns on its profitability. GLUE is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

GLUE had positive earnings in the past year.
GLUE had a positive operating cash flow in the past year.
GLUE had negative earnings in each of the past 5 years.
GLUE had negative operating cash flow in 4 of the past 5 years.
GLUE Yearly Net Income VS EBIT VS OCF VS FCFGLUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

With an excellent Return On Assets value of 1.56%, GLUE belongs to the best of the industry, outperforming 90.86% of the companies in the same industry.
GLUE has a Return On Equity of 2.24%. This is amongst the best in the industry. GLUE outperforms 91.94% of its industry peers.
Industry RankSector Rank
ROA 1.56%
ROE 2.24%
ROIC N/A
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
GLUE Yearly ROA, ROE, ROICGLUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

GLUE has a Profit Margin of 3.86%. This is amongst the best in the industry. GLUE outperforms 91.58% of its industry peers.
The Operating Margin and Gross Margin are not available for GLUE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 3.86%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GLUE Yearly Profit, Operating, Gross MarginsGLUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

More info and screens

6

2. Health

2.1 Basic Checks

GLUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GLUE has been increased compared to 1 year ago.
Compared to 5 years ago, GLUE has more shares outstanding
GLUE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GLUE Yearly Shares OutstandingGLUE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
GLUE Yearly Total Debt VS Total AssetsGLUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

GLUE has an Altman-Z score of 1.47. This is a bad value and indicates that GLUE is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of GLUE (1.47) is better than 68.28% of its industry peers.
GLUE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 1.47
ROIC/WACCN/A
WACC9.68%
GLUE Yearly LT Debt VS Equity VS FCFGLUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

GLUE has a Current Ratio of 5.61. This indicates that GLUE is financially healthy and has no problem in meeting its short term obligations.
GLUE has a Current ratio (5.61) which is in line with its industry peers.
GLUE has a Quick Ratio of 5.61. This indicates that GLUE is financially healthy and has no problem in meeting its short term obligations.
GLUE has a Quick ratio (5.61) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.61
Quick Ratio 5.61
GLUE Yearly Current Assets VS Current LiabilitesGLUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

GLUE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 102.78%, which is quite impressive.
The Revenue has grown by 14889.38% in the past year. This is a very strong growth!
EPS 1Y (TTM)102.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%205.66%
Revenue 1Y (TTM)14889.38%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7882.05%

3.2 Future

Based on estimates for the next years, GLUE will show a decrease in Earnings Per Share. The EPS will decrease by -8.21% on average per year.
Based on estimates for the next years, GLUE will show a very strong growth in Revenue. The Revenue will grow by 22.64% on average per year.
EPS Next Y43.71%
EPS Next 2Y-20%
EPS Next 3Y-12.74%
EPS Next 5Y-8.21%
Revenue Next Year330.64%
Revenue Next 2Y30.81%
Revenue Next 3Y28.85%
Revenue Next 5Y22.64%

3.3 Evolution

GLUE Yearly Revenue VS EstimatesGLUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
GLUE Yearly EPS VS EstimatesGLUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 -2

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 74.71, the valuation of GLUE can be described as expensive.
Based on the Price/Earnings ratio, GLUE is valued cheaper than 91.58% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.19. GLUE is valued rather expensively when compared to this.
The Forward Price/Earnings Ratio is negative for GLUE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 74.71
Fwd PE N/A
GLUE Price Earnings VS Forward Price EarningsGLUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, GLUE is valued cheaper than 96.95% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.56
EV/EBITDA -40.71
GLUE Per share dataGLUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A cheap valuation may be justified as GLUE's earnings are expected to decrease with -12.74% in the coming years.
PEG (NY)1.71
PEG (5Y)N/A
EPS Next 2Y-20%
EPS Next 3Y-12.74%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GLUE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MONTE ROSA THERAPEUTICS INC

NASDAQ:GLUE (7/15/2025, 8:00:01 PM)

After market: 5.23 0 (0%)

5.23

-0.03 (-0.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-07 2025-08-07/bmo
Inst Owners100.9%
Inst Owner Change0%
Ins Owners0.85%
Ins Owner Change0.06%
Market Cap321.70M
Analysts84
Price Target16.61 (217.59%)
Short Float %14.53%
Short Ratio20.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)671.65%
Min EPS beat(2)262.91%
Max EPS beat(2)1080.39%
EPS beat(4)4
Avg EPS beat(4)351.7%
Min EPS beat(4)21.93%
Max EPS beat(4)1080.39%
EPS beat(8)7
Avg EPS beat(8)168.99%
EPS beat(12)10
Avg EPS beat(12)113.41%
EPS beat(16)12
Avg EPS beat(16)31.41%
Revenue beat(2)2
Avg Revenue beat(2)433.62%
Min Revenue beat(2)422.32%
Max Revenue beat(2)444.91%
Revenue beat(4)4
Avg Revenue beat(4)338.3%
Min Revenue beat(4)241.21%
Max Revenue beat(4)444.91%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.74%
PT rev (3m)-2.56%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.49%
EPS NY rev (1m)54.88%
EPS NY rev (3m)62.38%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-24.21%
Revenue NY rev (1m)7.65%
Revenue NY rev (3m)66.76%
Valuation
Industry RankSector Rank
PE 74.71
Fwd PE N/A
P/S 2.02
P/FCF 10.56
P/OCF 9.28
P/B 1.17
P/tB 1.17
EV/EBITDA -40.71
EPS(TTM)0.07
EY1.34%
EPS(NY)-1.47
Fwd EYN/A
FCF(TTM)0.5
FCFY9.47%
OCF(TTM)0.56
OCFY10.78%
SpS2.59
BVpS4.47
TBVpS4.47
PEG (NY)1.71
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.56%
ROE 2.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 3.86%
GM N/A
FCFM 19.11%
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 50.66%
Cap/Sales 2.63%
Interest Coverage N/A
Cash Conversion 564.37%
Profit Quality 495.34%
Current Ratio 5.61
Quick Ratio 5.61
Altman-Z 1.47
F-Score8
WACC9.68%
ROIC/WACCN/A
Cap/Depr(3y)233.13%
Cap/Depr(5y)356.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)102.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%205.66%
EPS Next Y43.71%
EPS Next 2Y-20%
EPS Next 3Y-12.74%
EPS Next 5Y-8.21%
Revenue 1Y (TTM)14889.38%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7882.05%
Revenue Next Year330.64%
Revenue Next 2Y30.81%
Revenue Next 3Y28.85%
Revenue Next 5Y22.64%
EBIT growth 1Y98.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.61%
EBIT Next 3Y2.85%
EBIT Next 5YN/A
FCF growth 1Y127.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y139.18%
OCF growth 3YN/A
OCF growth 5YN/A